Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
17 Results for "
IMR-32 neuroblastoma cells
" in MedChemExpress (MCE) Product Catalog:
Products (17)
17 Results for "IMR-32 neuroblastoma cells" in MCE Product Catalog:
Cat. No.: HY-171767
CAS No.: 3038446-94-2
Synonyms: JB325
Target:
Research Areas:
SK2188 (JB325) is a selective AURKA PROTAC degrader with a DC50 of 3.9 nM. SK2188 recruits CRBN E3 ubiquitin ligase to target and degrade AURKA, abrogating both its catalytic and non-kinase functions, which leads to the destabilization and degradation of the oncogenic protein MYCN, ultimately inducing replication stress, DNA damage and apoptosis. SK2188 is applicable to research related to neuroblastoma .
Cat. No.: HY-P1047
CAS No.: 182912-74-9
Synonyms: [Pro18, Asp21] β-Amyloid (17-21)
Target:
Research Areas:
β-Sheet Breaker Peptide iAβ5 ([Pro18, Asp21] β-Amyloid (17-21)) is an amyloid fibril disaggregation inducer. β-Sheet Breaker Peptide iAβ5 inhibits fibril formation and disaggregates preformed fibrils by binding to the central hydrophobic region of Aβ (LVFFA) and disrupting the interactions between Aβ monomers/oligomers. β-Sheet Breaker Peptide iAβ5 reproducibly induces the disaggregation of fibrillar amyloid deposits in rat brain. β-Sheet Breaker Peptide iAβ5 prevents and reverses Aβ-induced neuronal shrinkage, reduces IL-1β-positive microglia surrounding Aβ deposits, and decreases the size of cerebral amyloid plaques. β-Sheet Breaker Peptide iAβ5 labeled with HBA enables blue quantitative detection under acidic conditions. β-Sheet Breaker Peptide iAβ5 is used in research related to Alzheimer's disease .
Cat. No.: HY-W011762
CAS No.: 255906-59-3
VK3-OCH3 is a potent antitumor agent. VK3-OCH3 shows cytotoxicity for neuroblastoma cell lines and low cytotoxicity for normal cell lines. VK3-OCH3 induces apoptosis and cell cycle arrest at G2/M phase in IMR-32 cells. VK3-OCH3 shows antitumor activity .
Cat. No.: HY-136479
CAS No.: 361198-09-6
F0911-7667 is a SIRT1 activator that induces autophagic cell death in U87MG and T98G cells by activating the AMPK-mTOR-ULK complex. CWR tripeptide was also identified as a SIRT1 activator that reduced p53 acetylation in IMR32 neuroblastoma cells and protected cells from cell death induced by Aβ fragments .
Cat. No.: HY-172609
CAS No.: 1809556-48-6
Target:
Research Areas:
SL-176 is a PPM1D (Wip1) inhibitor. SL-176 inhibits lipid droplet formation, downregulates the mRNA and protein expression of PPARγ and C/EBPα, and blocks adipocyte differentiation. SL-176 induces G2/M cell cycle arrest, apoptosis and inhibits cell proliferation in breast cancer cells overexpressing PPM1D, and activates components of the p53 pathway. SL-176 suppresses tumor growth in a zebrafish model of neuroblastoma. SL-176 is applicable to research related to obesity, breast cancer and neuroblastoma .
Cat. No.: HY-N10890
CAS No.: 1041740-13-9
Category:
Target:
Cat. No.: HY-176734
Target:
Research Areas:
CZL-S092 is a PLK4 inhibitor with an IC50 value of 0.9 nM and excellent selectivity over other PLK4 family members (PLK1, PLK2, and PLK3). CZL-S092 exhibits anti-neuroblastoma activity in vitro (IMR-32 cells, IC50 = 1.143 μM). CZL-S092 inhibits cell migration and halts the cell cycle and induces apoptosis. CZL-S092 can be used in studies of various cancers including neuroblastoma cancer .
Target:
Research Areas:
nAChR agonist 1 is a potent, blood-brain-barrier-permeable, and orally active allosteric modulator of α7 nicotinic acetylcholine receptor (α7 nAChR). nAChR agonist 1 has the EC50 of 0.32 μM in a Ca 2+ mobilization assay (PNU-282987-induced, FLIPR based) in human IMR-32 neuroblastoma cells that endogenously express α7 nAChR. nAChR agonist 1 can be develpoped for the treatment of Alzheimer’s disease .
Cat. No.: HY-N15215
CAS No.: 1004319-60-1
Target:
Cat. No.: HY-114901
CAS No.: 186141-75-3
Target:
Research Areas:
A-134974 is a selective adenosine kinase (ADK) inhibitor, with an IC50 of 0.06 nM and 45 nM in rat brain cytoplasmic ADK enzyme assays and intact IMR-32 cells, respectively . A-134974 inhibits adenosine phosphorylation and elevates intracellular and extracellular adenosine levels, alleviates neuropathic tactile allodynia and inflammatory thermal hyperalgesia via endogenous adenosine signaling in the spinal cord, and shows favorable dose separation between its analgesic effects and motor function impairment . A-134974 can be used in research on neuropathic pain, inflammatory pain, RNA silencing and thermoregulation .
Cat. No.: HY-118974
CAS No.: 225925-12-2
Target:
Research Areas:
PD-151307 is an N-type calcium channel antagonist with significant inhibitory effects in IMR-32 human neuroblastoma cells, exhibiting an IC50 of 0.32 µM. PD-151307 can be used in research related to cancer therapy, anticonvulsants, and neuropathic pain .
Cat. No.: HY-187506
Target:
Research Areas:
ZSL-M028 is an orally active and selective Polo-like kinase 4 (PLK4) inhibitor with an IC50 value of 1.1 nM. ZSL-M028 exhibits anti-tumor activity against TRIM37-amplified neuroblastoma, downregulates SAS6, upregulates FBXW5, induces G2-phase cell cycle arrest and apoptosis, activates the p53 signaling pathway, and inhibits tumor cell colony formation and migration. ZSL-M028 shows significant tumor growth inhibitory activity in the IMR-32 neuroblastoma xenograft model. ZSL-M028 can be used in neuroblastoma-related research .
Cat. No.: HY-181568
CAS No.: 3115344-59-4
Research Areas:
PROTAC Aurora A Degrader-1 is an orally active and blood-brain barrier-permeable selective Aurora A PROTAC degrader. PROTAC Aurora A Degrader-1 induces AURKA degradation with a DC50 of 6 nM in IMR32 cells (Dmax = 95%), eliminates both the kinase catalytic activity and N-Myc stabilizing scaffolding function of Aurora A, induces DNA damage, G2/M arrest and apoptosis, and shows antiproliferative activity. PROTAC Aurora A Degrader-1 is applicable to the research of neuroblastoma and small cell lung cancer .
Cat. No.: HY-120679A
CAS No.: 157434-99-6
Synonyms: NSC 697887 sodium
Target:
Research Areas:
XK469 (NSC 697887) sodium is a quinoxaline-based topoisomerase II inhibitor. XK469 sodium exhibits antiproliferative activity against neuroblastoma cells. XK469 sodium can be used in the research of neuroblastoma .
Cat. No.: HY-181911
Target:
Research Areas:
L2-FK866 is an ADC payload-linker conjugate (Drug-linker conjugate for ADC). L2-FK866 contains the ADC linker (Val-Cit-p-aminobenzyl) and the NAMPT inhibitor FK866 (HY-50876). L2-FK866 can be conjugated with Dinutuximab (HY-P9933) to form an ADC. L2-FK866 is applicable to neuroblastoma research .
Target:
Cat. No.: HY-182351
CAS No.: 253306-39-7
Target:
Research Areas:
ONO-2921 is an orally active and selective N-type calcium channel blocker. ONO-2921 functionally blocks N-type calcium channels. ONO-2921 reduces paw withdrawal responses during persistent nociception and hyperalgesia to heat in neuropathic pain models. ONO-2921 can be used for research on neuropathic pain and nociceptive pain .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
